Case report: Successful remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Behçet's disease

Front Immunol. 2024 Nov 8:15:1483993. doi: 10.3389/fimmu.2024.1483993. eCollection 2024.

Abstract

Background: The limited therapeutic options and inconsistent treatment efficacy of Intestinal Behçet's disease complicate its management, with the absence of standardized guidelines further exacerbating the challenges faced by clinicians.

Case presentation: In this case report, we present a patient with refractory intestinal Behçet's disease who experienced treatment failure with prior biologic agents. This case sheds light on managing this complex scenario with Janus kinase (JAK) inhibitors, the patient achieved mucosal healing after switching to Upadacitinib.

Conclusion: This case underscores the potential of Upadacitinib as an effective alternative for managing difficult cases of intestinal Behçet's disease.

Keywords: anti-TNF-refractory; case report; intestinal Behçet’s disease; mucosal healing; upadacitinib.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Behcet Syndrome* / complications
  • Behcet Syndrome* / drug therapy
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Intestinal Diseases / drug therapy
  • Intestinal Diseases / etiology
  • Janus Kinase Inhibitors / therapeutic use
  • Male
  • Remission Induction*
  • Treatment Outcome
  • Tumor Necrosis Factor Inhibitors / therapeutic use
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • upadacitinib
  • Heterocyclic Compounds, 3-Ring
  • Janus Kinase Inhibitors
  • Tumor Necrosis Factor Inhibitors
  • Tumor Necrosis Factor-alpha

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by grants from the youth program of Shaanxi Natural Science Foundation (No. 2022SF-195).